Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

Innovation and night light in large and small cities. by Saul Estrin (8629173)

Subjects:

Geographical distribution of large cities and small cities. by Saul Estrin (8629173)

Subjects:

Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

Table of step height. by Jianbo Jia (717814)

Subjects:

The well wall step. by Jianbo Jia (717814)

Subjects:

Table 5_Road transportation is associated with decreased intestinal motility in horses.docx by Sharanne L. Raidal (3097719)

“…Horses with high heart rates, high sweat scores or abnormal demeanour on arrival demonstrated decreased intestinal motility. Salivary cortisol concentrations increased after transportation (mean difference, 95% CI, for T0 vs T1 was 1.66, 1.09−2.53 nmol/L) and were inversely associated with intestinal motility. …”

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

Subjects:

Mann Whitney U test applied to differences in rates of decision switching (instances of yes, no and reconsider expressed as a proportion of the total reponses) of students and radi... by Clare Rainey (11677747)

The standard deviation of the mean total population abundance was calculated at each time step. by Cyrine Chenaoui (22177098)

Algorithm operation steps. by Junyan Wang (4738518)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects: